Dr. Sue Sisley is identified for her perform in studying the effects of marijuana on unique health-related ailments such as PTSD. Her business, Scottsdale Investigation Institute, has filed a lawsuit against the Drug Enforcement Administration (DEA) in an try to have their application to develop marijuana for investigation purposes processed.

The suit alleges that the DEA’s stance on working with marijuana grown only at the University of Mississippi for investigation purposes has made a monopoly, Westword reports. Sisley indicates that UM’s marijuana is low-grade and delivers small range.

Sisley pointed out that the marijuana supplied to researchers consists of indica and sativa strains mixed with each other, which creates problems when attempting to ascertain how a distinct marijuana strain impacts a certain overall health situation/symptom.

“Most scientists finish up with this mishmash of unique strains (such as stem sticks, leaves, and so on.) — all of it appears to get thrown into a grinder in an overzealous work to standardize the study drug batches for clinical trials,” mentioned Sisley. “I’m arguing that by performing that, they’re overprocessing the plant and decimating the organic efficacy contained in the flowering tops. Additional, in controlled trials, we concern sufferers the study drug by weight.”

In 2016, the DEA mentioned it was going to permit far more men and women to develop cannabis for investigation purposes. Because that announcement, no more licenses have been issued. The DEA has received more than 30 applications from parties interested in expanding marijuana for investigation.

Sisley stated, “Maintaining only one particular federally legal drug provide for any clinical trials in the U.S. has been a big impediment to investigation, due to the fact it is not permitting scientists access to important solutions. We cannot just study from one particular supplier who appears to be restricted from buying new genetics. And when there’s a monopoly for this lots of decades, it tends to breed apathy. There’s no true drive to respond to the public, to be responsive to the demands of scientists, no true have to have to innovate in the path of what sufferers want.”

A DEA spokesperson says that it is “still operating by means of the approach and these applications stay beneath assessment.”

Robert Jordan/University of Mississippi by means of AP